Menon T Sanjay Kumar, Dileep Jude Ernest, Kuruvila Sheela, Kaliyaperumal Damayandhi, Sadasivam Ilakkia Priya, Dharanisankar Sushmitha, Jayabalan Gayathri, Mani Divya
Department of Dermatology, Venereology and Leprosy, Aarupadai Veedu Medical College and Hospital, Puducherry, India.
Indian J Dermatol Venereol Leprol. 2025 Jul-Aug;91(4):425-431. doi: 10.25259/IJDVL_1263_2024.
Background Treatment of keloids presents a significant therapeutic challenge due to their tendency to recur and their impact on a patient's quality of life. This randomised controlled trial aimed to compare the effectiveness of intralesional triple combination regimen versus intralesional triamcinolone acetonide monotherapy in treating keloids. Aims To compare the efficacy and safety of intralesional triple combination versus intralesional triamcinolone acetonide monotherapy in treating keloids at any site. Methods This study was conducted in the outpatient department of Dermatology, Venereology and Leprosy in a tertiary care hospital at Puducherry. Seventy two patients aged ≥18 years with a clinical diagnosis of keloids of any duration, involving any site and without any prior treatment were included in the study. Patients were randomised into two groups: Group A received intralesional triple combination (triamcinolone acetonide, 5-fluorouracil and hyaluronidase), while Group B received intralesional triamcinolone acetonide monotherapy. Treatments were administered every three weeks for four sessions or till complete flattening, whichever was earlier. The Vancouver Scar Scale was used for assessment at baseline and every three weeks for four sessions, and monthly for three months post treatment. Results Both groups showed significant improvement in the Vancouver Scar Scale scores at each follow-up compared to baseline. The mean (percentage) improvement in the Vancouver Scar Scale score in Group A was 0.58 ± 0.5 (7.08%) at three weeks, which progressively increased to 4.47 ± 1.29 (54.55%) at the final follow-up. In Group B, the improvement was lesser, with 0.08 ± 0.28 (0.95%) at three weeks, increasing to 3.08 ± 0.81 (36.65%) at the final follow-up. This improvement was significantly more in Group A at all time points compared to Group B (p < 0.05). Post-procedure pain, which lasted for a few hours, was noted in three and two patients in Groups A and B, respectively (p = 0.642). None of the patients had a recurrence of keloids during the study. Limitations Limitations of this study include small sample size, single centre design, short follow-up period, lack of blinding and patient-reported outcome measures, which may impact the generalisability of the findings. Conclusion Intralesional triple combination is more effective than triamcinolone acetonide monotherapy in treating keloids, offering significantly superior improvements in the Vancouver Scar Scale scoring.
瘢痕疙瘩的治疗面临重大挑战,因为它们易于复发,且会影响患者的生活质量。这项随机对照试验旨在比较病灶内三联组合疗法与病灶内注射曲安奈德单一疗法治疗瘢痕疙瘩的有效性。
比较病灶内三联组合疗法与病灶内注射曲安奈德单一疗法治疗任何部位瘢痕疙瘩的疗效和安全性。
本研究在本地治里一家三级护理医院的皮肤科、性病科和麻风病科门诊进行。纳入72名年龄≥18岁、临床诊断为瘢痕疙瘩、病程不限、累及任何部位且未接受过任何先前治疗的患者。患者被随机分为两组:A组接受病灶内三联组合疗法(曲安奈德、5-氟尿嘧啶和透明质酸酶),而B组接受病灶内注射曲安奈德单一疗法。每三周进行一次治疗,共四次,或直至完全扁平,以先达到者为准。在基线时以及每三周进行一次,共四次,治疗后三个月每月进行一次,使用温哥华瘢痕量表进行评估。
与基线相比,两组在每次随访时温哥华瘢痕量表评分均有显著改善。A组在三周时温哥华瘢痕量表评分的平均(百分比)改善为0.58±0.5(7.08%),在最终随访时逐渐增加至4.47±1.29(54.55%)。B组的改善较小,三周时为0.08±0.28(0.95%),在最终随访时增加至3.08±0.81(36.65%)。在所有时间点,A组的改善均显著高于B组(p<0.05)。A组和B组分别有3名和2名患者出现持续数小时的术后疼痛(p=0.642)。在研究期间,没有患者出现瘢痕疙瘩复发。
本研究的局限性包括样本量小、单中心设计、随访期短、缺乏盲法和患者报告的结局指标,这可能会影响研究结果的普遍性。
病灶内三联组合疗法在治疗瘢痕疙瘩方面比曲安奈德单一疗法更有效,在温哥华瘢痕量表评分方面有显著更好的改善。